Goldman Sachs
TCON

Goldman Sachs’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Goldman Sachs’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-538
Closed -$42K – 6763
2021
Q3 		$42K Buy
+538
New +$45.5K ﹤0.01% 6077
2021
Q1 		– Sell
-1,049
Closed -$246K – 6419
2020
Q4 		$246K Buy
1,049
+96
+10% +$13.4K ﹤0.01% 4985
2020
Q3 		$99K Buy
+953
New +$51K ﹤0.01% 5095
2018
Q4 		– Sell
-133
Closed -$55K – 5778
2018
Q3 		$55K Buy
+133
New +$61.6K ﹤0.01% 5275

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's TCON Position: Q4 2021 in Review

Goldman Sachs sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2021, closing a stake of 538 shares — an estimated $42K sold.

Goldman Sachs first reported a position in TCON in Q3 2018 and held it in 4 quarters. The position peaked at $246K in Q4 2020. 35 funds tracked by Wall St. Rank hold TCON as of Q4 2021.

  • Goldman Sachs reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 538 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $42K.
  • Goldman Sachs first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 4 quarters.
  • Goldman Sachs's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $246K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.